Orbimed Advisors LLC, Director at Scribe Therapeutics, Inc. (SCTX), bought 1,000,000 shares at $15.00 ($15.0M) on 2026-07-27, disclosed to the SEC on 2026-07-29.
Orbimed Advisors LLC purchased 1 million shares of Scribe Therapeutics for $15.0M, marking the largest insider purchase in the company's history and signaling strong conviction in its genetic editing platform. This significant capital commitment comes shortly after the company raised $125M in its IPO to fund clinical trials aimed at preventing heart attacks.
Scribe shares are currently trading at $18.46, up 30% since the July 30 IPO, and are 6.31% above the 52-week low of $17.365, though they remain 27.05% below the 52-week high of $25.305.
1) Q3 earnings on 2026-10-29; 2) Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com, 2026-07-30) regarding the funding of three clinical trials; 3) Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO (GuruFocus.com, 2026-07-24) regarding the $440.3M valuation backed by Sanofi and Eli Lilly.
The stock remains significantly below its 52-week high of $25.305, indicating that the current price of $18.46 is still down 27.05% from that peak, which may reflect market skepticism about the commercial viability of the genetic editing therapies.
Nothing distinguishes this filing.
| Filing → |
| BRVE | BUY | 2026-08-11 | $34.9M | — | Filing → |
| SION | SELL | 2026-07-09 | $3.9M | — | Filing → |
| SION | SELL | 2026-07-02 | $5.3M | — | Filing → |